Interferon Beta-1a Injection for MS
A recombinant interferon beta-1a formulation for relapsing multiple sclerosis treatment, regulating immune processes. Falls under HTS 3002.90.52.50 as an immunological product (interferon) prepared for therapeutic use via biotechnological methods. It reduces disease activity in neurological conditions.
Import Duty Rates by Country of Origin
Alternative Classifications
This product could be classified differently depending on its characteristics or intended use.
If categorized under specific blood fractions
Narrower subheadings apply to certain defined interferons or interleukins.
If for non-immunological peptide hormones
Synthetic peptides not regulating immunology go to Chapter 29.
If mixed with excipients for oral/ other forms
Mixed medicinal preparations shift to heading 3003 or 3004.
Not sure which classification is right?
Our AI classifier can analyze your specific product and recommend the correct HTS code with confidence.
Import Tips & Compliance
• Include recombinant DNA origin docs and bioequivalence studies for biologics approval
• Use validated cold chain with temperature excursions monitored for protein integrity
• Specify therapeutic dosing to distinguish from research cytokines
Related Products under HTS 3002.90.52.50
Human Serum Albumin USP 25% Solution
A sterile solution of human serum albumin at 25% concentration, prepared from human plasma for therapeutic use in treating hypovolemia and shock. It falls under HTS 3002.90.52.50 as a blood fraction prepared for therapeutic use, derived from human blood through fractionation processes. This immunological product supports plasma volume expansion in clinical settings.
IVIG Intravenous Immunoglobulin 10% Infusion
A pooled immunoglobulin G preparation from human plasma, used therapeutically for primary immunodeficiency and autoimmune disorders. Classified under HTS 3002.90.52.50 as an immunological product and blood fraction obtained via biotechnological purification. It modulates immune responses in patients with antibody deficiencies.
Monoclonal Antibody Infliximab Biosimilar
A recombinant chimeric monoclonal antibody targeting TNF-alpha, used for treating inflammatory conditions like rheumatoid arthritis. It qualifies under HTS 3002.90.52.50 as an immunological product directly involved in immune regulation, produced via biotechnological processes. Administered intravenously for therapeutic purposes.
Recombinant Human Erythropoietin Alfa
A biotechnologically produced hematopoietin stimulating red blood cell production, used in anemia treatment for chronic kidney disease patients. Classified in HTS 3002.90.52.50 as an immunological product (hematopoietin) for therapeutic use. It is a growth factor directly involved in blood cell regulation.
Anti-Hemophilic Factor VIII Concentrate
A plasma-derived or recombinant Factor VIII concentrate for preventing bleeding in hemophilia A patients. It is a blood fraction and immunological product under HTS 3002.90.52.50, prepared for therapeutic prophylactic use. Essential for clotting factor replacement therapy.
Botulinum Toxin Type A for Therapeutic Use
Purified botulinum toxin type A complex, indicated for cervical dystonia and spasticity management. Falls under HTS 3002.90.52.50 as a toxin prepared for therapeutic use, a culture-derived product modulating neuromuscular transmission. Used in measured doses for neurological conditions.